Info: Read More
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • How to Order
  • Delivery time
  • Science | Nature | Cell | View More
    Natural Products
    Scopolamine
    Information
    CAS No. 51-34-3 Price $108 / 20mg
    Catalog No.CFN98200Purity>=98%
    Molecular Weight303.35Type of CompoundAlkaloids
    FormulaC17H21NO4Physical DescriptionOil
    Download Manual    COA    MSDS    SDFSimilar structuralComparison (Web)  (SDF)
    Citing Use of our Products
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
    Size /Price /Stock 10 mM * 1 mL in DMSO / $38.8 / In-stock
    Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
    Our products had been exported to the following research institutions and universities, And still growing.
  • Michigan State University (USA)
  • University of Illinois (USA)
  • Universidad de Buenos Aires (Argentina)
  • Copenhagen University (Denmark)
  • The Vancouver Prostate Centre (... (Canada)
  • Sanford Burnham Prebys Medical ... (USA)
  • Universidad Miguel Hernández (Spain)
  • University of Wisconsin-Madison (USA)
  • Univerzita Karlova v Praze (Czech Republic)
  • Warszawski Uniwersytet Medyczny (Poland)
  • Universidade Católica Portuguesa (Portugal)
  • More...
  • Package
    Featured Products
    4-O-Feruloylquinic acid

    Catalog No: CFN92392
    CAS No: 2613-86-7
    Price: $/mg
    Przewalskin

    Catalog No: CFN99306
    CAS No: 119400-87-2
    Price: $398/5mg
    Kushenol X

    Catalog No: CFN92390
    CAS No: 254886-77-6
    Price: $568/5mg
    Platycodigenin

    Catalog No: CFN92207
    CAS No: 22327-82-8
    Price: $268/10mg
    3-Epioleanolic acid

    Catalog No: CFN92068
    CAS No: 25499-90-5
    Price: $318/10 mg
    Isochlorogenic acid B

    Catalog No: CFN99119
    CAS No: 14534-61-3
    Price: $70/20mg
    Dihydrocucurbitacin B

    Catalog No: CFN92140
    CAS No: 13201-14-4
    Price: $318/10mg

    Scopolamine

    Scopolamine
    Product Name Scopolamine
    CAS No.: 51-34-3
    Catalog No.: CFN98200
    Molecular Formula: C17H21NO4
    Molecular Weight: 303.35 g/mol
    Purity: >=98%
    Type of Compound: Alkaloids
    Physical Desc.: Oil
    Targets: AChR | 5-HT3 receptor | M1 muscarinic receptor | M2 muscarinic receptor
    Source: The herbs of Atropa belladonna L.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Price: $108 / 20mg
    Inquire / Order: manager@chemfaces.com
    Technical Inquiries: service@chemfaces.com
    Tel: +86-27-84237783
    Fax: +86-27-84254680

    Address:
    1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
  • Nutraceutical Research . 2021, 19(1),p90-105.
  • Molecules.2018, 23(9):E2121
  • J of the Society of Cosmetic Scientists of Korea2018, 44(4):407-417
  • Nutrients.2020, 12(3):595.
  • Ind Crops Prod.2014, 62:173-178
  • J Nat Med.2020, 74(3):550-560.
  • Chemistr of plant2016, 2016021195
  • J AOAC Int.2021, 104(6):1634-1651.
  • Int J Oncol.2019, 55(1):320-330
  • Nutrients.2020, 12(12):3638.
  • Related Screening Libraries
    Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
    10 mM * 1 mL in DMSO / Inquiry / In-stock
    Related Libraries
  • Sedative hypnotics Compound Library
  • Damage memory Compound Library
  • Alkaloids Compound Library
  • AChR Inhibitor Library
  • Biological Activity
    Description: Scopolamine is a high affinity (nM) muscarinic antagonist. 5-HT3 receptor-responses are reversibly inhibited by Scopolamine with an IC50 of 2.09 μM. Scopolamine can cause learning and memory impairments and galantamine can reverse the symptom. It also can produce rapid and significant symptom improvement in patients with depression.
    Targets: AChR | 5-HT3 receptor | M1 muscarinic receptor | M2 muscarinic receptor
    In vivo:
    J Med Food. 2014 Oct;17(10):1049-56.
    Rubus coreanus Miquel ameliorates scopolamine-induced memory impairments in ICR mice.[Pubmed: 25121635]
    The present study investigated the effect of Rubus coreanus Miquel (RCM) on Scopolamine-induced memory impairments in ICR mice.
    METHODS AND RESULTS:
    Mice were orally administrated RCM for 4 weeks and Scopolamine was intraperitoneally injected into mice to induce memory impairment. RCM improved the Scopolamine-induced memory impairment in mice. The increase of acetylcholinesterase activity caused by Scopolamine was significantly attenuated by RCM treatment. RCM increased the levels of acetylcholine in the brain and serum of mice. The expression of choline acetyltransferase, phospho-cyclic AMP response element-binding protein, and phospho-extracellular signal-regulated kinase was significantly increased within the brain of mice treated with RCM. The brain antioxidant enzyme activity decreased by Scopolamine was increased by RCM.
    CONCLUSIONS:
    These results demonstrate that RCM exerts a memory-enhancing effect via the improvement of cholinergic function and the potentiated antioxidant activity in memory-impaired mice. The results suggest that RCM may be a useful agent for improving memory impairment.
    Invert Neurosci. 2014 Sep;14(2):91-101.
    Galantamine reverses scopolamine-induced behavioral alterations in Dugesia tigrina.[Pubmed: 24402079]
    In planaria (Dugesia tigrina), Scopolamine, a nonselective muscarinic receptor antagonist, induced distinct behaviors of attenuated motility and C-like hyperactivity.
    METHODS AND RESULTS:
    Planarian locomotor velocity (pLMV) displayed a dose-dependent negative correlation with Scopolamine concentrations from 0.001 to 1.0 mM, and a further increase in Scopolamine concentration to 2.25 mM did not further decrease pLMV. Planarian hyperactivity counts was dose-dependently increased following pretreatment with Scopolamine concentrations from 0.001 to 0.5 mM and then decreased for Scopolamine concentrations ≥ 1 mM. Planarian learning and memory investigated using classical Pavlovian conditioning experiments demonstrated that Scopolamine (1 mM) negatively influenced associative learning indicated by a significant decrease in % positive behaviors from 86 % (control) to 14 % (1 mM Scopolamine) and similarly altered memory retention, which is indicated by a decrease in % positive behaviors from 69 % (control) to 27 % (1 mM Scopolamine). Galantamine demonstrated a complex behavior in planarian motility experiments since co-application of low concentrations of galantamine (0.001 and 0.01 mM) protected planaria against 1 mM Scopolamine-induced motility impairments; however, pLMV was significantly decreased when planaria were tested in the presence of 0.1 mM galantamine alone. Effects of co-treatment of Scopolamine and galantamine on memory retention in planaria via classical Pavlovian conditioning experiments showed that galantamine (0.01 mM) partially reversed Scopolamine (1 mM)-induced memory deficits in planaria as the % positive behaviors increased from 27 to 63 %.
    CONCLUSIONS:
    The results demonstrate, for the first time in planaria, Scopolamine's effects in causing learning and memory impairments and galantamine's ability in reversing Scopolamine-induced memory impairments.
    J Affect Disord. 2014 Jun;162:39-42.
    Antidepressant treatment history as a predictor of response to scopolamine: clinical implications.[Pubmed: 24767003]
    The intravenous administration of Scopolamine produces rapid antidepressant effects. Generally, failing multiple previous antidepressant trials is associated with a poor prognosis for response to future medications. This study evaluated whether treatment history predicts antidepressant response to Scopolamine.
    METHODS AND RESULTS:
    Treatment resistant patients (2 failed medication trials) (n=31) and treatment naïve patients (no exposure to psychotropic medication) (n=31) with recurrent major depressive or bipolar disorder participated in a double-blind, placebo-controlled, crossover clinical trial. Following a placebo lead-in, participants randomly received P/S or S/P (P=3 placebo; S=3 Scopolamine (4ug/kg) sessions 3 to 5 days apart). The Montgomery-Asberg Depression Rating Scale (MADRS) was the primary outcome measure. A linear mixed model was used to examine the interaction between clinical response and treatment history, adjusting for baseline MADRS. Treatment resistant and treatment naïve subjects combined responded significantly to Scopolamine compared to placebo (F=15.06, p<0.001). Reduction in depressive symptoms was significant by the first post-Scopolamine session (F=42.75, p<0.001). A treatment history by Scopolamine session interaction (F=3.37, p=0.04) indicated treatment naïve subjects had lower MADRS scores than treatment resistant patients; this was significant after the second Scopolamine infusion (t=2.15, p=0.03). Post-hoc analysis: Also, we used a single regimen to administer Scopolamine, and smokers were excluded from the sample, limiting generalizability.
    CONCLUSIONS:
    Treatment naïve and treatment resistant patients showed improved clinical symptoms following Scopolamine, while those who were treatment naïve showed greater improvement. Scopolamine rapidly reduces symptoms in both treatment history groups, and demonstrates sustained improvement even in treatment resistant patients.
    Afr J Tradit Complement Altern Med . 2017 Mar 1;14(3):136-141.
    COGNITIVE-ENHANCING PROPERTIES OF MORINDA LUCIDA (RUBIACEAE) AND PELTOPHORUM PTEROCARPUM (FABACEAE) IN SCOPOLAMINE-INDUCED AMNESIC MICE[Pubmed: 28480424]
    Abstract Background: Cognitive disorders associated with aging have been successfully managed by African traditional medical practitioners using various plants. This study evaluated the cognitive enhancing potentials of Morinda lucida (L) Rubiaceae and Peltophorum pterocarpum (DC) ex. K Heyne in Scopolamine induced amnesic animals. Materials and methods: The anti-amnesic activity of the ethyl acetate extracts of Morinda lucida and Peltophorum pterocarpum at doses of 4 mg/kg, 6 mg/kg and 8 mg/kg were assessed in Scopolamine induced amnesic mice using Morris water maze test model. Effect of the extracts on the histology of the hippocampus was also evaluated. Results: The ethyl acetate extract of Morinda lucida and Peltophorum pterocarpum ameliorated Scopolamine induced memory deficit in the animals under study. There was no effect of the extract on the histology of the hippocampus. However, there was an increase in the density of cells in the hippocampus of treated group as compared to the untreated. Conclusion: Morinda lucida and Peltophorum pterocarpum showed considerable enhancement of cognition in Scopolamine induced amnesic mice. Keywords: Hippocampus; Morinda lucida; Morris water maze; Peltophorum pterocarpum;
    Indian J Pharmacol . Jan-Feb 2017;49(1):60-64.
    Evaluation of neuroprotective effect of quercetin with donepezil in scopolamine-induced amnesia in rats[Pubmed: 28458424]
    Abstract Objective: The objective of this study was to evaluate the neuroprotective effect of quercetin with donepezil in Scopolamine-induced amnesia in rats. Materials and methods: Five groups of adult male Wistar rats (12 months old) weighing 180-200 g (n = 6) were used. The normal control group received normal saline and test group animals were pretreated orally with quercetin (25 mg/kg), donepezil (3 mg/kg), and a combination of quercetin (25 mg/kg) with donepezil (3 mg/kg), respectively, dosed at every 24 h interval for 14 consecutive days, afterward amnesia was induced by Scopolamine (3 mg/kg) on the 14th day through intraperitoneal route. Cognitive performance was assessed by the Morris water maze, elevated plus maze, and passive avoidance paradigm. Acetylcholinesterase enzyme (AchE) level, biochemical markers such as lipid peroxidase (LPO), glutathione (GSH), β amyloid1-42level, and histopathological study of rat brain were estimated. Statistical analysis was done by one-way analysis of variance, followed by Dunnett's post hoc test. P ≥ 0.05 was considered statistically significant. Results: Pretreatment with quercetin, donepezil, and their combination showed a significant increase in escape latency, step-through latency, and decreased transfer latency in respective cognitive models of the Morris water maze, passive avoidance test, and elevated plus maze. Further coadministration significantly decreased AchE level, β amyloid1-42level as compared to individual therapy. Biochemical markers such as elevated GSH, decreased LPO were observed, and histopathological studies revealed the reversal of neuronal damage in the treatment group (P < 0.05) as compared to Scopolamine-treated control group. Conclusion: Pretreatment with quercetin potentiates the action of donepezil in Scopolamine-induced amnesia in rats. The improved cognitive memory could be due to the synergistic effect of the drugs by decreasing AchE level, β amyloid1-42level, and antioxidant action in rat brain. Keywords: Acetylcholinesterase enzyme; amnesia; donepezil; quercetin; Scopolamine.
    Scopolamine Description
    Source: The herbs of Atropa belladonna L.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    ChemFaces New Products and Compounds
    Methylpicraquassioside B

    Catalog No: CFN95379
    CAS No: 1443757-89-8
    Price: $318/10mg
    Glucoliquiritin

    Catalog No: CFN95011
    CAS No: 93446-18-5
    Price: $318/10mg
    Cassiaside C

    Catalog No: CFN95120
    CAS No: 119170-52-4
    Price: $318/10mg
    (3beta,22alpha)-26-(beta-glucopyra...

    Catalog No: CFN95321
    CAS No: 107783-53-9
    Price: $318/20mg
    Citrusin B

    Catalog No: CFN95178
    CAS No: 105279-10-5
    Price: $388/5mg
    Quercetin 3-O-beta-D-glucosyl-(1->...

    Catalog No: CFN95277
    CAS No: 143016-74-4
    Price: $318/10mg
    2-Methoxy-5-acetoxy-furanogermacr-...

    Catalog No: CFN95197
    CAS No: 1809980-25-3
    Price: $318/10mg
    Phloretin 3',5'-Di-C-glucoside

    Catalog No: CFN95306
    CAS No: 357401-40-2
    Price: $318/10mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.2965 mL 16.4826 mL 32.9652 mL 65.9304 mL 82.4131 mL
    5 mM 0.6593 mL 3.2965 mL 6.593 mL 13.1861 mL 16.4826 mL
    10 mM 0.3297 mL 1.6483 mL 3.2965 mL 6.593 mL 8.2413 mL
    50 mM 0.0659 mL 0.3297 mL 0.6593 mL 1.3186 mL 1.6483 mL
    100 mM 0.033 mL 0.1648 mL 0.3297 mL 0.6593 mL 0.8241 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Protocol
    Animal Research:
    J Pharmacol Exp Ther. 2014 Nov;351(2):448-56.
    M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine.[Pubmed: 25187432]
    Scopolamine produces rapid and significant symptom improvement in patients with depression, and most notably in patients who do not respond to current antidepressant treatments. Scopolamine is a nonselective muscarinic acetylcholine receptor antagonist, and it is not known which one or more of the five receptor subtypes in the muscarinic family are mediating these therapeutic effects.
    METHODS AND RESULTS:
    We used the mouse forced-swim test, an antidepressant detecting assay, in wild-type and transgenic mice in which each muscarinic receptor subtype had been genetically deleted to define the relevant receptor subtypes. Only the M1 and M2 knockout (KO) mice had a blunted response to Scopolamine in the forced-swim assay. In contrast, the effects of the tricyclic antidepressant imipramine were not significantly altered by gene deletion of any of the five muscarinic receptors. The muscarinic antagonists biperiden, pirenzepine, and VU0255035 (N-[3-oxo-3-[4-(4-pyridinyl)-1-piper azinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide) with selectivity for M1 over M2 receptors also demonstrated activity in the forced-swim test, which was attenuated in M1 but not M2 receptor KO mice. An antagonist with selectivity of M2 over M1 receptors (SCH226206 [(2-amino-3-methyl-phenyl)-[4-[4-[[4-(3 chlorophenyl)sulfonylphenyl]methyl]-1-piperidyl]-1-piperidyl]methanone]) was also active in the forced-swim assay, and the effects were deleted in M2 (-/-) mice. Brain exposure and locomotor activity in the KO mice demonstrated that these behavioral effects of Scopolamine are pharmacodynamic in nature.
    CONCLUSIONS:
    These data establish muscarinic M1 and M2 receptors as sufficient to generate behavioral effects consistent with an antidepressant phenotype and therefore as potential targets in the antidepressant effects of Scopolamine.
    4-O-Feruloylquinic acid

    Catalog No: CFN92392
    CAS No: 2613-86-7
    Price: $/mg
    Przewalskin

    Catalog No: CFN99306
    CAS No: 119400-87-2
    Price: $398/5mg
    Kushenol X

    Catalog No: CFN92390
    CAS No: 254886-77-6
    Price: $568/5mg
    Platycodigenin

    Catalog No: CFN92207
    CAS No: 22327-82-8
    Price: $268/10mg
    3-Epioleanolic acid

    Catalog No: CFN92068
    CAS No: 25499-90-5
    Price: $318/10 mg
    Isochlorogenic acid B

    Catalog No: CFN99119
    CAS No: 14534-61-3
    Price: $70/20mg
    Dihydrocucurbitacin B

    Catalog No: CFN92140
    CAS No: 13201-14-4
    Price: $318/10mg